Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Recruiting now · Phase 1
Conditions studied: Solid Tumors
In brief
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Key facts
- Study ID
- NCT06963281
- Run by
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- People needed
- 285
- Starts
- 2025-04-29
- Expected to finish
- 2028-03-31
- Last updated by the study team
- 2025-06-06
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must satisfy all of the following criteria to be enrolled into the study:
- Participants have the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
- Male or female participants ≥ 18 years old. For Part 1, age ≥ 18 years and ≤ 75 years;
- Histologically or cytologically confirmed unresectable, locally advanced or metastatic solid tumors which have received available standard therapies and have disease progression, or unacceptable toxic effects, or contraindications;
- At least 1 measurable lesion as defined per RECIST v1.1 within 28 days prior to the first dose of IBI3020;
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1;
- Minimum life expectancy of 12 weeks;
- Adequate bone marrow and organ function confirmed at screening period;
- Participants, both male and female, who are not of childbearing potential or who agree to use at least 1 highly effective method of contraception during the study.
You may not qualify if…
- Participants who meet any of the following criteria will be disqualified from entering the study:
- Previous treatment with CEACAM5-targeted therapy;
- Prior anti-cancer therapy within the wash-out period;
- Received live vaccines within 4 weeks or cancer vaccine within 3 months;
- Potent cytochrome P450 3A4 (CYP3A4) inhibitors within 2 weeks or 5 half-lives;
- Has adverse reactions resulting from previous anti-tumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI CTCAE v5.0;
- Known allergies, hypersensitivity, or intolerance to IBI3020 or its excipients;
- Undergone major surgery within 4 weeks, or who have severe unhealed wounds;
- Known symptomatic central nervous system (CNS) metastases;
- Uncontrolled diseases or conditions;
- History of pneumonitis requiring corticosteroids therapy, or history of clinically significant lung diseases;
- History of thromboembolic event within 6 months;
- Under neurological, psychiatric or social condition;
- Women who are pregnant, have positive results in pregnancy test or are lactating;
- Not eligible to participate in this study at the discretion of the investigator;
- Participating in any other interventional clinical research.
Where it is running
- Mayo Clinic - Arizona — Pheonix, Arizona, United States (enrolling)
- Mayo Clinic - Florida — Jacksonville, Florida, United States (enrolling)
- Mayo Clinic - Rochester — Rochester, Minnesota, United States (enrolling)
- Montefiore Cancer Center — New York, New York, United States (enrolling)
- NEXT Houston — Houston, Texas, United States (enrolling)
- NEXT Dallas — Irving, Texas, United States (enrolling)
- The sixth affiliated hospital, Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)
- Shandong Cancer Hospital — Jinan, Shandong, China (enrolling)
- Shanxi Cancer Hospital — Taiyuan, Shanxi, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.